1. Ministry of Health & Wefare. Korea Population and Health Welfare Association. Blood sample records for neonatal screening test and external quality assessment for inborn errors of metabolism in Korea, 2013.
2. Clinical and Laboratory Standards Institute. Newborn screening for preterm, low birth weight, and sick newborns; approved guideline. CLSI document NBS03-A (Replaces I/LA 31-P). Wayne PA: Clinical and Laboratory Standards Institute;2009.
3. Clinical and Laboratory Standards Institute. Newborn screening by tandem mass spectrometry; approved guideline. CLSI document NBS04-A (formerly I/LA32-A). Wayne PA: Clinical and Laboratory Standards Institute;2010.
4. Yoon HR, Lee KR, Kang S, Lee DH, Yoo HW, Min WK, et al. Screening of newborns and high-risk group of children for inborn metabolic disorders using tandem mass spectrometry in South Korea: a three-year report. Clin Chim Acta. 2005; 354:167–180.
5. Zytkovicz TH, Fitzgerald EF, Marsden D, Larson CA, Shih VE, Johnson DM, et al. Tandem mass spectrometric analysis for amino, organic, and fatty acid disorders in newborn dried blood spots: a two-year summary from the New England Newborn Screening Program. Clin Chem. 2001; 47:1945–1955.
7. McHugh D, Cameron CA, Abdenur JE, Abdulrahman M, Adair O, Al Nuaimi SA, et al. Clinical validation of cutoff target ranges in newborn screening of metabolic disorders by tandem mass spectrometry: a worldwide collaborative project. Genet Med. 2011; 13:230–254.
8. Marquardt G, Currier R, McHugh DM, Gavrilov D, Magera MJ, Matern D, et al. Enhanced interpretation of newborn screening results without analyte cutoff values. Genet Med. 2012; 14:648–655.
10. Song SM, Yoon HR, Lee AN, Lee KR. Seven-year experience with inherited metabolic disorders screening by tandem mass spectrometry. J Genet Med. 2008; 5:21–25.
11. Lee EH. Inherited metabolic disorders screening by tandem mass spectrometry: assessment and future prospect through two-year experience. J Genet Med. 2003; 3:94–96.
12. Yu CL, Gu XF. Newborn screening of inherited metabolic diseases by tandem mass spectrometry. Beijing Da Xue Xue Bao. 2006; 38:103–106.
13. Niu DM, Chien YH, Chiang CC, Ho HC, Hwu WL, Kao SM, et al. Nationwide survey of extended newborn screening by tandem mass spectrometry in Taiwan. J Inherit Metab Dis. 2010; 33:S295–S305.
14. Levy PA. An overview of newborn screening. J Dev Behav Pediatr. 2010; 31:622–631.
15. Brusilow SW, Maestri NE. Urea cycle disorders: diagnosis, pathophysiology, and therapy. Adv Pediatr. 1996; 43:127–170.
16. Clinical and Laboratory Standards Institute. Newborn screening follow-up; approved guideline. CLSI document NBS02-A2 (replaces I/LA 27-A). Wayne PA: Clinical and Laboratory Standards Institute;2013.
17. Lee YW, Lee DH, Vockley J, Kim ND, Lee YK, Ki CS. Different spectrum of mutations of isovaleryl-CoA dehydrogenase (IVD) gene in Korean patients with isovaleric acidemia. Mol Genet Metab. 2007; 92:71–77.
18. Lee YW, Lee DH, Kim ND, Lee ST, Ahn JY, Choi TY, et al. Mutation analysis of PAH gene and characterization of a recurrent deletion mutation in Korean patients with phenylketonuria. Exp Mol Med. 2008; 40:533–540.
19. Park HD, Lee DH, Choi TY, Lee YK, Kim JW, Ki CS, et al. Clinical, biochemical, and genetic analysis of a Korean neonate with hereditary tyrosinemia type 1. Clin Chem Lab Med. 2009; 47:930–933.
20. Woo HI, Park HD, Lee YW, Lee DH, Ki CS, Lee SY, et al. Clinical, biochemical and genetic analyses in two Korean patients with medium-chain acyl-CoA dehydrogenase deficiency. Korean J Lab Med. 2011; 31:54–60.
21. Park HD, Lee DH, Hong YH, Kang DH, Lee YK, Song J, et al. Three Korean patients with maple syrup urine disease: four novel mutations in the BCKDHA gene. Ann Clin Lab Sci. 2011; 41:167–173.
22. Kim HJ, Park SJ, Park KI, Lee JS, Eun HS, Kim JH, et al. Acute treatment of hyperammonemia by continuous renal replacement therapy in a newborn patient with ornithine transcarbamylase deficiency. Korean J Pediatr. 2011; 54:425–428.
23. Woo HI, Ki CS, Lee SY, Kim JW, Song J, Jin DK, et al. Mutation spectrum of the ASS1 gene in Korean patients with citrullinemia type 1. Clin Biochem. 2013; 46:209–213.
24. Forman J, Coyle F, Levy-Fisch J, Roberts P, Terry S, Legge M. Screening criteria: the need to deal with new developments and ethical issues in newborn metabolic screening. J Community Genet. 2013; 4:59–67.